

## CORRESPONDENCE

Anesthesiology  
79:631, 1993  
© 1993 American Society of Anesthesiologists, Inc.  
J. B. Lippincott Company, Philadelphia

## The Importance of *In Vitro* Assay Temperature When Using Volatile Anesthetics

**To the Editor:**—The recent report by El-Maghrabi and Eckenhoff demonstrated that halothane and isoflurane disrupted [ $^3\text{H}$ ]dopamine transport into synaptosomes from rat brain.<sup>1</sup> The authors suggest that the clinical relevance of this observation is validated, at least in part, by the fact that the  $\text{IC}_{50}$  of the inhibition by halothane was 0.7 mm at 22° C. Equilibration of 1% v/v halothane (1 MAC in rats)<sup>2</sup> with Tris buffer at 37° C results in an aqueous halothane concentration of 0.4 mm.<sup>3</sup>

We believe that the extrapolation of results obtained using volatile anesthetics at below physiologic temperatures must be qualified before any claim of clinical relevance can be maintained. Inhibition of amine transport by halothane at physiologic temperature would hold more credence with regard to clinical relevance than would similar inhibition at room temperature. That amine transport processes are temperature-dependent leads us to only speculate as to why the authors failed to measure anesthetic influences on dopamine transport at 37° C.

We maintain that this shortcoming fails to allow any valid extension of these results to the *in vivo* situation. In reporting the inhibition of [ $^3\text{H}$ ]5-hydroxytryptamine (5-HT) transport by halothane at 37° C, we noted a somewhat less potent effect than the present results, where the  $\text{IC}_{50}$  value for halothane was approximately 1.0 mm.<sup>4</sup> Moreover, contrary to what El-Maghrabi and Eckenhoff stated, we noted a competitive kinetic interaction between halothane and 5-HT transport, implying an action by the anesthetic at the 5-HT transport recognition site.

**Dan C. Martin, M.D.**  
Associate Professor  
Departments of Anesthesiology  
and Pharmacology and Toxicology

**Robert G. Merin, M.D.**  
Professor  
Department of Anesthesiology

Medical College of Georgia  
Augusta, Georgia 30912-2700

### References

1. El-Maghrabi EA, Eckenhoff RG: Inhibition of dopamine transport in rat brain synaptosomes by volatile anesthetics. *ANESTHESIOLOGY* 78: 750–756, 1993
2. Mazze RI, Rice SA, Baden JM: Halothane, isoflurane, and enflurane MAC in pregnant and nonpregnant female and male mice and rats. *ANESTHESIOLOGY* 62:339–341, 1985
3. Martin DC, Pruett JK, Aronstam RS: Test-tube equilibration of volatile anaesthetic concentrations. *Br J Anaesth* 70:365–367, 1993
4. Martin DC, Adams RJ, Introna RPS: Halothane inhibits 5-hydroxytryptamine uptake by synaptosomes from rat brain. *Neuropharmacology* 29:9–16, 1990

(Accepted for publication June 22, 1993.)

Anesthesiology  
79:631–632, 1993  
© 1993 American Society of Anesthesiologists, Inc.  
J. B. Lippincott Company, Philadelphia

**In Reply:**—Martin and Merin raise at least two temperature-related issues, one being the influence of temperature on transport processes and the other being the relationship between temperature and volatile anesthetic concentration. There is no question that dopamine transport is temperature-dependent. This is the reason why the kinetic assays reported in our paper<sup>1</sup> were performed at 37° C; a fact clearly stated in the methods section. Only the inhibition experiments were performed at 22° C—to slow the initial rate of uptake and reduce the time-dependency of the assay. We have made the reasonable assumption that the  $\text{IC}_{50}$  value is *temperature-independent*, as verified by our finding that  $V_{\text{max}}$  in the presence of anesthetics (at 37° C) was reduced by an amount predicted by the 22° C  $\text{IC}_{50}$ .<sup>1</sup>

To examine the issue of temperature dependence of anesthetic concentrations, it is important to remember that anesthetic effects are ultimately related to the *molar concentration*, and not the gas

concentration, despite the anesthesiologists' fixation on minimum alveolar concentration (really a compromise for measurement convenience and generally valid because of the relatively constant temperature of our patients). If the molar concentration is produced by equilibration with a gas phase, then temperature is important, because of the temperature-dependent nature of blood or buffer/gas partition coefficients. For example, 0.35 mm halothane in Krebs' buffer is produced by equilibration with about 1.0 vol% at 37° C or 0.5 vol% at 22° C. However, if the anesthetic is dissolved directly in a gas-tight system with no gas space (as we did), then the molar concentration is *temperature-independent*. Because most potency data for these agents are expressed in vol%, it is necessary for laboratory investigators to relate the (measured) molar concentration back to the clinically familiar gas concentration. In doing so, it is crucial that 37° C partition coefficients be used, regardless of the actual experiment's tempera-

## CORRESPONDENCE

ture. The related and important question of how temperature influences partitioning between blood or buffer and the "effect" site is less well answered because the character of this site is not known. The small and inconsistent effect of temperature on buffer/tissue partition coefficients suggests, however, that this influence is small.

Lastly, though the [ $^3\text{H}$ ]5-hydroxytryptamine (5-HT) and dopamine transporters are members of the same family, they are different proteins, so the fact that halothane may produce slightly different effects in one as compared to the other should not be surprising. What is perhaps surprising is the similarity between our results and those of Martin *et al.*<sup>2</sup> They reported that isoflurane inhibited 5-HT transport noncompetitively, and at a  $\text{IC}_{50}$  of 2.36 mM, compared to our non-competitive  $\text{IC}_{50}$  for dopamine transport of 2.24 mM. Their data for halothane are less clear, however, because in one paper<sup>3</sup> they conclude that the inhibition of 5-HT transport showed competitive kinetics but then reported in a subsequent paper<sup>4</sup> that the inhibition was allosteric with respect to the 5-HT site (*i.e.*, noncompetitive). Martin and Merin do not discuss this apparent discrepancy in their letter or the Martin *et al.* paper,<sup>4</sup> but it has become increasingly clear that it is not a discrepancy at all; allosteric interactions can produce competitive kinetics, as is well documented by the situation with cocaine and the dopamine transporter,<sup>5,6</sup> for example. Overall then, it seems that our results are in rather good agreement with those of Martin and Merin, despite the minor methodologic differences.

We stand by our conclusion that dopamine transporter inhibition occurs with concentrations of halothane, but not isoflurane, that are used clinically. How or whether this can be reconciled with an *in vivo* effect, is not yet clear.

**Essam El-Maghrabi, M.D.**  
Resident in Anesthesia

**Roderic G. Eckenhoff, M.D.**  
Assistant Professor of Anesthesia and Physiology

Department of Anesthesia  
University of Pennsylvania Medical Center  
Philadelphia, Pennsylvania 19104

## References

1. El-Maghrabi EA, Eckenhoff RG: Inhibition of dopamine transport in rat brain synaptosomes by volatile anesthetics. *ANESTHESIOLOGY* 78: 750–756, 1993
2. Martin DC, Adams RJ, Aronstam RS: The influence of isoflurane on the synaptic activity of 5-HT. *Neurochem Res* 15:969–973, 1990
3. Martin DC, Adams RJ, Introna RPS: Halothane inhibits 5-hydroxytryptamine uptake by synaptosomes from rat brain. *Neuropharmacology* 29:9–16, 1990
4. Martin DC, Introna RP, Aronstam RS: Inhibition of neuronal 5-HT uptake by ketamine, but not halothane, involves disruption of substrate recognition by the transporter. *Neurosci Lett* 112:99–103, 1990
5. Krueger BK: Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. *J Neurochem* 55:260–267, 1990
6. Kitayama S, Shimada S, Xu H, Markham L, Donovan DM, Uhl GR: Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. *Proc Natl Acad Sci USA* 89: 7782–7785, 1992

(Accepted for publication June 22, 1993.)